Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 1,666 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: High Dose Drug A Clear all

Conditions: Advanced Non Small Cell Lung Cancer
Interventions: ATL001, Pembrolizumab; Biological · Drug
Lead sponsor: Achilles Therapeutics UK Limited; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 3
States / cities: New Haven, Connecticut • Tampa, Florida • New York, New York

Conditions: Safety Issues, Tolerance
Interventions: Treatment 1, Treatment 2, Placebo; Dietary Supplement
Lead sponsor: USANA Health Sciences; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Sedation, Respiration, Artificial, Length of Stay
Interventions: Dexmedetomidine, Normal Saline; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Crohn Disease
Interventions: JNJ-64304500, Placebo, Ustekinumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 388 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 37
States / cities: Lone Tree, Colorado • Coral Gables, Florida • Kissimmee, Florida + 34 more

Conditions: Myelodysplastic Syndromes
Interventions: CPX-351, Research skin biopsy, Research blood draw, Research bone marrow aspirate; Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 3
States / cities: Tampa, Florida • St Louis, Missouri • Seattle, Washington

Conditions: Small Cell Lung Carcinoma (SCLC)
Interventions: BI 764532, Topotecan, Single agent chemotherapy; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Jacksonville, Florida • Miami, Florida + 1 more

Conditions: Diabetic Nephropathy
Interventions: Lisinopril, Nifedipine, Simvastatin; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 1999
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Influenza
Interventions: Fluzone Quadrivalent vaccine, no preservative (0.5-mL), 2019-2020 formulation, Fluzone High-Dose vaccine, 2019-2020 formulation; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months to 83 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 2
States / cities: Bardstown, Kentucky • Salt Lake City, Utah

Conditions: Osteosarcoma Metastatic
Interventions: Cisplatin liposomal; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 13 Years to 50 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 2
States / cities: New York, New York

Conditions: Coronary Artery Disease
Interventions: High dose potent statin, ACE-I (lisinopril) or ARB (losartan), Aspirin 81 enteric coated tablet daily, Lifestyle Counseling, Quality of Life Questionnaires; Drug · Behavioral
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 2,476 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 80
States / cities: Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 54 more

Conditions: Cocaine Dependency
Interventions: CPP-115, Placebo; Drug
Lead sponsor: Catalyst Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Non-small Cell Lung Cancer
Interventions: HS110 vaccine, Placebo; Biological
Lead sponsor: Heat Biologics; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine, Etoposide, Laboratory Biomarker Analysis, Melphalan, Peripheral Blood Stem Cell Transplantation, Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8; Procedure · Drug · Other + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: HIV
Interventions: AGT103-T; Biological
Lead sponsor: American Gene Technologies International Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Washington D.C., District of Columbia

Conditions: Leber Hereditary Optic Neuropathy (LHON)
Interventions: NR082 Injection, Injection needle; Drug · Device
Lead sponsor: Neurophth Therapeutics Inc; Other
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 3
States / cities: Palo Alto, California • Aurora, Colorado • Philadelphia, Pennsylvania

Conditions: Hypercholesterolaemia
Interventions: Alirocumab, Placebo, Lipid-Modifying Therapy (LMT), Antihyperglycemic Drug; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 517 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 29
States / cities: Encino, California • Fresno, California • Oakland, California + 25 more

Conditions: Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
Interventions: Low dose of quadrivalent VLP vaccine, Medium dose of quadrivalent VLP vaccine, High dose of quadrivalent VLP vaccine, Placebo; Biological
Lead sponsor: Medicago; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Hollywood, Florida • Miami, Florida

Conditions: Asthma
Interventions: Daily Text message reminder, Inhaled steroid canister monitor; Behavioral · Device
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 4 Years to 11 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Interventions: NS-863 Low Dose, NS-863 High Dose, Placebo; Drug · Other
Lead sponsor: NS Pharma, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Vasodilatory Hypotension During or After Cardiac Surgery
Interventions: Angiotensin II; Drug
Lead sponsor: University of Maryland St. Joseph Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Towson, Maryland

Conditions: Non-Hodgkin Lymphoma, Large B-cell Lymphoma
Interventions: Axicabtagene Ciloleucel; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Thyroid Eye Disease, Graves Orbitopathy, Endocrine System Diseases, Eye Diseases, Thyroid Associated Ophthalmopathy, Graves Ophthalmopathy, Thyroid Diseases, Orbital Diseases, Proptosis, IGF1R, Exophthalmos, Hashimoto
Interventions: linsitinib; Drug
Lead sponsor: Sling Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Miami, Florida • Morgantown, West Virginia

Conditions: Early-stage Parkinson's Disease
Interventions: UCB0599, Placebo; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 496 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 57
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more

Conditions: Fibromyalgia, Neurocognition
Interventions: Milnacipran, Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC

Safety and Tolerability of 2 Dietary Supplement Beverages Designed to Maintain Healthy Blood Pressure.

Dexmedetomidine for Postoperative Sedation in Patients Undergoing Repair of Thoracoabdominal Aortic Aneurysms

Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease

CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome

DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy

Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes

Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively

Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung

Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD

A Safety, Tolerability and Pharmacokinetic Study of CPP-115

Immune Response and Safety of HS110 Vaccine in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer

Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies

Study to Evaluate the Safety of a Gene and Cell Therapy Product in Participants With HIV That is Well-Controlled on Antiretroviral Therapy

Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND4 Mutations

Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)

Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in Adults

Asthma Controller Adherence After Hospitalization

A Clinical Trial of NS-863 in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

ANG-First Trial (Angiotensin II as First-Line Vasopressor Therapy in Cardiac Surgery)

Axicabtagene Ciloleucel Reinfusion(Axi-Cel-2) in Relapsed/Refractory 2nd Line High-Risk NHL

Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease

Milnacipran and Neurocognition, Pain and Fatigue in Fibromyalgia : A 13-week Randomized, Placebo Controlled Cross Over Trial